journal article·2018-07-04Open access

Nanocarriers in advanced drug targeting: setting novel paradigm in cancer therapeutics

Md. Habban Akhter, Md. Rizwanullah, Javed Ahmad, Mohamed Jawed Ahsan, Md. Ali Mujtaba, Saima Amin

Abstract

Cancer has been growing nowadays consequently high number of death ascertained worldwide. The medical intervention involves chemotherapy, radiation therapy and surgical removal. This conventional technique lacking targeting potential and harm the normal cells. In drug treatment regimen, the combination therapy is preferred than single drug treatment module due to higher internalization of chemotherapeutics in the cancer cells both by enhance permeation retention effect and by direct cell apoptosis. The cancer therapeutics involves different methodologies of delivering active moiety to the target site. The active and passive transport mode of chemotherapeutic targeting utilizes advance nanocarriers. The nanotechnological strategic treatment applying advance nanocarrier greatly helps in mitigating the cancer prevalence. The nanocarrier-incorporating nanodrug directed for specific area appealed scientist across the globe and issues to be addressed in this regard. Therefore, various techniques and approaches invented to meet the objectives. With the advances in nanomedicine and drug delivery, this review briefly focused on various modes of nanodrug delivery including nanoparticles, liposomes, dendrimer, quantum dots, carbon nanotubes, metallic nanoparticles, nanolipid carrier (NLC), gold nanoshell, nanosize cantilevers and nanowire that looks promising and generates a novel horizon in cancer therapeutics.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Graphene and Nanomaterials Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard (Hamdard University), New Delhi, India;

Department of Pharmaceutics, Najran University, Najran, Saudi Arabia;

Department of Pharmaceutical Chemistry, Maharishi Arvind College of Pharmacy, Jaipur, Rajasthan, India;

Department of Pharmaceutics, Faculty of Pharmacy, Northern Border University, Rafha, Saudi Arabia

References (89)

Show source-provided references
1. 10.2741/s10310.2741/s103 ↗
2. 10.2147/IJN.S59610.2147/IJN.S596 ↗
3. 10.1016/j.jconrel.2010.08.02710.1016/j.jconrel.2010.08.027 ↗
4. Ehrlich P. The collected papers of Paul Ehrlich. London: Pergamon; 1960. p. 3.
5. 10.4161/cbt.2.6.54910.4161/cbt.2.6.549 ↗
6. 10.1016/S0936-6555(05)80269-910.1016/S0936-6555(05)80269-9 ↗
7. 10.1097/01.cad.0000167902.53039.5a10.1097/01.cad.0000167902.53039.5a ↗
8. WHO. Ultraviolet radiation. Skin cancers. 2016. Available from: www.who.int/uv/faq/skincancer/en/index1.html
9. 10.1016/j.addr.2013.09.01910.1016/j.addr.2013.09.019 ↗
10. 10.3389/fphar.2015.0021910.3389/fphar.2015.00219 ↗
11. 10.1016/j.ejps.2012.12.00610.1016/j.ejps.2012.12.006 ↗
12. Cancer Quest. 2016. Available from: https://www.cancerquest.org/cancer-biology/angiogenesis?gclid
13. 10.2165/11317600-000000000-0000010.2165/11317600-000000000-00000 ↗
14. 10.2174/156720181166614082211251610.2174/1567201811666140822112516 ↗
15. 10.2174/138161204338346710.2174/1381612043383467 ↗
16. 10.1016/j.addr.2014.05.00510.1016/j.addr.2014.05.005 ↗
17. 10.2174/138920101566614060814323510.2174/1389201015666140608143235 ↗
18. 10.1016/j.addr.2004.10.01010.1016/j.addr.2004.10.010 ↗
19. 10.1016/j.addr.2012.09.04110.1016/j.addr.2012.09.041 ↗
20. 10.1158/0008-5472.CAN-05-419910.1158/0008-5472.CAN-05-4199 ↗
21. 10.3109/21691401.2016.114673110.3109/21691401.2016.1146731 ↗
22. 10.1158/0008-5472.CAN-06-211710.1158/0008-5472.CAN-06-2117 ↗
23. 10.1016/j.clim.2006.06.00610.1016/j.clim.2006.06.006 ↗
24. 10.1073/pnas.091414010710.1073/pnas.0914140107 ↗
25. 10.1021/mp400590410.1021/mp4005904 ↗
26. 10.1016/j.biomaterials.2014.11.00810.1016/j.biomaterials.2014.11.008 ↗
27. 10.1016/j.cbpa.2009.03.02210.1016/j.cbpa.2009.03.022 ↗
28. 10.2147/IJN.S3262010.2147/IJN.S32620 ↗
29. 10.1021/mp800024g10.1021/mp800024g ↗
30. 10.1021/mp200042810.1021/mp2000428 ↗
31. 10.1021/acs.molpharmaceut.6b0087010.1021/acs.molpharmaceut.6b00870 ↗
32. 10.1038/nrc162710.1038/nrc1627 ↗
33. 10.1159/00008847810.1159/000088478 ↗
34. 10.1038/nrc274810.1038/nrc2748 ↗
35. 10.1093/jnci/dji13010.1093/jnci/dji130 ↗
36. 10.1007/s10555-006-7891-z10.1007/s10555-006-7891-z ↗
37. 10.3109/21691401.2014.94854810.3109/21691401.2014.948548 ↗
38. 10.3109/21691401.2014.94464610.3109/21691401.2014.944646 ↗
39. 10.1504/IJNM.2009.02811610.1504/IJNM.2009.028116 ↗
40. 10.1016/j.ijpharm.2012.03.02610.1016/j.ijpharm.2012.03.026 ↗
41. 10.1021/nn505051d10.1021/nn505051d ↗
42. 10.1016/j.bbamem.2007.12.02110.1016/j.bbamem.2007.12.021 ↗
43. 10.2147/IJN.S2416710.2147/IJN.S24167 ↗
44. 10.1166/jbn.2015.201910.1166/jbn.2015.2019 ↗
45. 10.1371/journal.pone.007223810.1371/journal.pone.0072238 ↗
46. 10.1016/j.ejpb.2015.06.01110.1016/j.ejpb.2015.06.011 ↗
47. 10.1016/j.biomaterials.2015.07.05510.1016/j.biomaterials.2015.07.055 ↗
48. Shah V · Clin Cancer Res · 2013 · 9:6193
49. 10.3892/mmr.2015.448710.3892/mmr.2015.4487 ↗
50. Ni M · Int J Nanomed · 2015 · 10 · 253710.2217/nnm.15.73 ↗
51. 10.18632/oncotarget.309010.18632/oncotarget.3090 ↗
52. 10.1016/j.jconrel.2007.12.01410.1016/j.jconrel.2007.12.014 ↗
53. 10.1016/j.biomaterials.2009.07.00810.1016/j.biomaterials.2009.07.008 ↗
54. 10.1080/21691401.2017.129064810.1080/21691401.2017.1290648 ↗
55. 10.1016/j.surfrep.2014.07.00110.1016/j.surfrep.2014.07.001 ↗
56. 10.1016/j.biomaterials.2011.03.05010.1016/j.biomaterials.2011.03.050 ↗
57. 10.1038/7852310.1038/78523 ↗
58. 10.3109/21691401.2016.116769710.3109/21691401.2016.1167697 ↗
59. 10.1615/CritRevTherDrugCarrierSyst.v20.i5.2010.1615/CritRevTherDrugCarrierSyst.v20.i5.20 ↗
60. 10.1038/nnano.2011.16610.1038/nnano.2011.166 ↗
61. 10.1038/mtna.2011.910.1038/mtna.2011.9 ↗
62. 10.1016/j.addr.2008.02.01210.1016/j.addr.2008.02.012 ↗
63. 10.1038/nbt117110.1038/nbt1171 ↗
64. The Economic Times. 2016. Available from: http://economictimes.indiatimes.com/articleshow/55974699.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
65. 10.1109/TNB.2005.85047810.1109/TNB.2005.850478 ↗
66. 10.1039/c2cc17995d10.1039/c2cc17995d ↗
67. 10.1021/nn800551s10.1021/nn800551s ↗
68. 10.1007/s12274-009-9009-810.1007/s12274-009-9009-8 ↗
69. 10.1039/B712350G10.1039/B712350G ↗
70. 10.1021/bc300248t10.1021/bc300248t ↗
71. 10.1016/j.biomaterials.2012.01.02510.1016/j.biomaterials.2012.01.025 ↗
72. 10.3109/1061186X.2013.77826410.3109/1061186X.2013.778264 ↗
73. 10.3109/21691401.2014.92788010.3109/21691401.2014.927880 ↗
74. 10.1021/nn405383a10.1021/nn405383a ↗
75. 10.1039/C5NR07785K10.1039/C5NR07785K ↗
76. 10.1039/C0JM02494E10.1039/C0JM02494E ↗
77. 10.3109/21691401.2014.90982210.3109/21691401.2014.909822 ↗
78. 10.1080/21691401.2016.117813410.1080/21691401.2016.1178134 ↗
79. Aberoumandi SM · Artif Cells Nanomed Biotechnol · 2016 · 45 · 1
80. 10.2147/IJN.S7783710.2147/IJN.S77837 ↗
81. 10.2147/IJN.S11751110.2147/IJN.S117511 ↗
82. Koopaei MN · Int J Nanomed · 2011 · 6 · 1903
83. 10.1016/j.ijpharm.2011.06.00110.1016/j.ijpharm.2011.06.001 ↗
84. In-Pharma Technologist.com. 2016. Available from: http://www.in-pharmatechnologist.com/Drug-Delivery/Gold-nanoshells-may-offer-new-delivery-option-for-cancer-hypothermia-drugs
85. 10.1088/1748-6041/9/2/02501210.1088/1748-6041/9/2/025012 ↗
86. 10.1002/smll.20120269410.1002/smll.201202694 ↗
87. 10.1016/j.jmmm.2014.10.10110.1016/j.jmmm.2014.10.101 ↗
88. 10.1002/anie.20120673710.1002/anie.201206737 ↗
89. 10.1021/acsami.6b0457910.1021/acsami.6b04579 ↗